Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31393494 | 0.88 | EPHX2 (0.54) | ALDH1A1RAB9ASMN1; SMN2NPC1CES2 | |
| SCHEMBL2311197 | 0.85 | MEN1 (0.49) | ALDH1A1MAPTHPGDCYP2C19RECQL | |
| SCHEMBL12876691 | 0.83 | CYP1A2 (0.47) | ALDH1A1HPGDCYP2C19CYP3A4L3MBTL1 | |
| SCHEMBL11701158 | 0.82 | TP53 (0.40) | ALOX5ALDH1A1MAPTHPGDCYP2C19 | |
| SCHEMBL3071125 | 0.82 | FFAR1 (0.45) | ALDH1A1MAPTHPGDCYP2C19RECQL | |
| SCHEMBL21515053 | 0.81 | P2RX7 (0.48) | ALDH1A1MAPTHPGDCYP2C19CYP3A4 | |
| SCHEMBL22046551 | 0.78 | CA1 (0.41) | ALDH1A1MAPTHPGDCYP2C19CYP3A4 | |
| SCHEMBL15930098 | 0.76 | HPGD (0.50) | ALDH1A1MAPTHPGDCYP2C19CYP3A4 | |
| SCHEMBL28593984 | 0.76 | F2R (0.45) | ALOX5ALDH1A1MAPTHPGDCYP2C19 | |
| SCHEMBL3069529 | 0.76 | CYP3A4 (0.43) | ALDH1A1MAPTCYP2C19RECQLCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809352-B2 | Sulfonamides as inhibitors of Bcl-2 family proteins for the treatments of cancer | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| WO-2009036035-A1 | BCL-2 INHIBITORS | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| EP-1318978-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024636-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | BCLAF1, BCL2L11, BCL2 | ALOX5 3063/4885ALDH1A1 2784/4885MAPT 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.